A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Adminstered ISIS 443139 in Patients With Early Manifest Huntington's Disease

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Adminstered ISIS 443139 in Patients With Early Manifest Huntington's Disease

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs IONIS HTTRx (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 23 Jun 2017 According to an Ionis Pharmaceuticals media release, dosing in the final patient cohort continues, and top-line results are expected around year-end 2017.
    • 22 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Mar 2017 Planned number of patients changed from 36 to 44.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top